STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
Open Access
- 1 January 2017
- journal article
- Published by Springer Nature in Blood Research
- Vol. 52 (4) , 293-299
Abstract
Jung SH, et al. Blood Res. 2017 Dec;52(4):293-299. https://doi.org/10.5045/br.2017.52.4.293Keywords
This publication has 30 references indexed in Scilit:
- Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple MyelomaCurrent Cancer Therapy Reviews, 2014
- Revisiting STAT3 signalling in cancer: new and unexpected biological functionsNature Reviews Cancer, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- Multiple myelomaThe Lancet, 2009
- Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in TumorsCancer Cell, 2009
- Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Blood, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Validating Stat3 in cancer therapyNature Medicine, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005